HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States.

@article{Hariri2015HPVTA,
  title={HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States.},
  author={Susan H Hariri and Elizabeth R. Unger and Sean M Schafer and Linda M. Niccolai and Ina U. Park and Karen C. Bloch and Nancy M. Bennett and Martin Steinau and Michelle L Johnson and Lauri Ellen Markowitz},
  journal={Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology},
  year={2015},
  volume={24 2},
  pages={393-9}
}
BACKGROUND Two currently available vaccines targeting human papillomavirus (HPV) types 16 and 18 could prevent 70% of cervical cancers and 50% of high-grade cervical lesions. Next-generation vaccines against additional types, such as a candidate 9-valent vaccine against HPV6/11/16/18/31/33/45/52/58, could further reduce HPV-associated disease burden… CONTINUE READING